| Asthma
Breo Ellipta vs Dulera
Side-by-side clinical, coverage, and cost comparison for asthma.Deep comparison between: Breo Ellipta vs Dulera with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsDulera has a higher rate of injection site reactions vs Breo Ellipta based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Dulera but not Breo Ellipta, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Breo Ellipta
Dulera
At A Glance
Oral inhalation
Once daily
ICS/LABA combination
Oral inhalation
Twice daily
ICS/LABA combination
Indications
- Chronic Obstructive Airway Disease
- Asthma
- Asthma
Dosing
Chronic Obstructive Airway Disease 1 actuation of BREO ELLIPTA 100/25 mcg once daily by oral inhalation; use a short-acting beta2-agonist for breakthrough symptoms between doses.
Asthma Adults >=18 years: 1 actuation of BREO ELLIPTA 100/25 mcg or 200/25 mcg once daily by oral inhalation; pediatric patients 12-17 years: 1 actuation of BREO ELLIPTA 100/25 mcg once daily; pediatric patients 5-11 years: 1 actuation of BREO ELLIPTA 50/25 mcg once daily; maximum dose is 1 inhalation of BREO ELLIPTA 200/25 mcg once daily.
Asthma (>=12 years) 2 inhalations twice daily of DULERA 100 mcg/5 mcg or 200 mcg/5 mcg via oral inhalation; maximum 2 inhalations of 200 mcg/5 mcg twice daily (800 mcg/20 mcg per day).
Asthma (5 to <12 years) 2 inhalations of DULERA 50 mcg/5 mcg twice daily via oral inhalation; maximum daily dose 200 mcg/20 mcg.
Contraindications
- Primary treatment of status asthmaticus or other acute episodes of COPD or asthma where intensive measures are required
- Severe hypersensitivity to milk proteins or demonstrated hypersensitivity to fluticasone furoate, vilanterol, or any excipient
- Primary treatment of status asthmaticus or acute episodes of asthma requiring intensive measures
- Known hypersensitivity to mometasone furoate, formoterol fumarate, or any ingredient in DULERA
Adverse Reactions
Most common (>=3%) nasopharyngitis, upper respiratory tract infection, oropharyngeal candidiasis, headache, back pain, pneumonia, bronchitis, sinusitis, cough, arthralgia, influenza, pharyngitis, pyrexia
Serious serious asthma-related events (hospitalizations, intubations, death), oropharyngeal candidiasis, pneumonia, immunosuppression, hypercorticism, adrenal suppression, paradoxical bronchospasm, cardiovascular effects, reduction in bone mineral density, growth effects, glaucoma, cataracts
Postmarketing palpitations, tachycardia, hypersensitivity reactions (anaphylaxis, angioedema, rash, urticaria), hyperglycemia, muscle spasms, tremor, nervousness, paradoxical bronchospasm
Most common (>=3%) Nasopharyngitis, sinusitis, headache; dysphonia reported at 4-5% in long-term (52-week) treatment; influenza, upper respiratory tract infection in pediatric patients aged 5 to <12 years.
Serious Serious asthma-related events (hospitalizations, intubations, death), cardiovascular and CNS effects, Candida albicans infection, immunosuppression, hypercorticism and adrenal suppression, growth effects in pediatrics, glaucoma and cataracts.
Postmarketing Angina pectoris, cardiac arrhythmias (atrial fibrillation, ventricular extrasystoles, tachyarrhythmia), vision blurred, anaphylactic reaction, angioedema, severe hypotension, rash, pruritus, QT prolongation, blood pressure increased, hypokalemia, hyperglycemia, asthma aggravation (cough, dyspnea, wheezing, bronchospasm).
Pharmacology
Breo Ellipta combines fluticasone furoate, a synthetic trifluorinated ICS that inhibits inflammation via glucocorticoid receptor activation, with vilanterol, a LABA that relaxes bronchial smooth muscle by stimulating beta2-adrenergic receptors and increasing intracellular cyclic AMP.
DULERA combines mometasone furoate, a synthetic corticosteroid with potent anti-inflammatory activity that inhibits multiple cell types and inflammatory mediators involved in the asthmatic response, and formoterol fumarate, a selective long-acting beta2-adrenergic receptor agonist (LABA) that relaxes bronchial smooth muscle by stimulating adenyl cyclase and inhibiting mast cell mediator release.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Breo Ellipta
- Covered on 5 commercial plans
- PA (3/12) · Step Therapy (0/12) · Qty limit (10/12)
Dulera
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (5/12) · Qty limit (10/12)
UnitedHealthcare
Breo Ellipta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Dulera
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Breo Ellipta
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (1/3)
Dulera
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (2/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Breo Ellipta.
No savings programs available for Dulera.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Breo ElliptaView full Breo Ellipta profile
DuleraView full Dulera profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.